---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206317"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:27:08.899979+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B

## Summary
- Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).
- Net loss $(125.9)M vs $(68.0)M YoY, includes $56.3M stock comp and $32.3M unrealized securities losses.
- Adjusted EBITDA $(2.8)M, improved from $(16.2)M in Q1 2025.
- Raised FY2026 revenue guidance to $1.59-1.60B (~25% annual growth); maintains ~$65M Adj. EBITDA outlook.
- MRD test volume ~6,500, up ~500% YoY; expanded collaborations with Merck, Gilead, Northwestern Medicine.

## SEC filing metadata
- accession: 0001193125-26-206317
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/0001193125-26-206317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/tem-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206317
- JSON: https://secwatch.observer/filing/0001193125-26-206317.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206317.txt

## Source-grounded claims
- claim_id: ebe259564bc2e023f7b03124f793a307272ce5c4
  claim: Tempus AI, Inc. reported the quarter ended March 31, 2026 results: revenue $348.1 million, net income ($125.9 million), EPS ($0.70). Guidance raised.
  evidence_excerpt: technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests
  evidence_url: https://www.sec.gov/Archives/edgar/data/1717115/000119312526206317/0001193125-26-206317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.